Harlan S. Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), completed two mandated stock sales on March 11, 2026, disposing of a combined 470,266 shares for approximately $6.19 million. Both trades were executed at a price of $13.17 per share.
The first of the two transactions involved the sale of 140,666 shares for about $1.85 million. The second transaction consisted of 329,600 shares, bringing in roughly $4.34 million. Together the two blocks total 470,266 shares and aggregate proceeds of approximately $6.19 million at the stated execution price.
Following these transactions, filings show Robins directly owns 1,851,658 shares and 1,522,058 shares of Adaptive Biotechnologies Corp. The record indicates the disposals were required by the company to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) and performance share units.
Adaptive Biotechnologies stock was trading at $13.17 at the time of the report. The share price has experienced notable volatility - posting an 80.91% gain over the past 12 months while declining 11.37% in the most recent week. According to InvestingPro analysis cited in the filings, ADPT appears overvalued relative to its Fair Value. Despite that assessment, sell-side analysts continue to carry price targets in the $20 to $22 range.
Other recent company developments
In separate disclosures, Adeptus Biotechnologies reported fourth-quarter 2025 results that beat expectations. The company posted earnings per share of -$0.09, ahead of the forecasted -$0.18, and reported revenue of $71.7 million, exceeding the expected $59.33 million.
Following that report, several firms adjusted their views. Piper Sandler reiterated an Overweight rating on Adeptus Biotechnologies. TD Cowen increased its price target to $21. BTIG raised its price target to $22, noting significant growth in the companys core Minimal Residual Disease business - 54% year-over-year in the fourth quarter and 46% for the full year.
Context and limitations
The transactions by Robins were described as mandatory to meet tax obligations tied to equity vesting. The public filings and cited InvestingPro commentary provide the bounds of analysis in this report. No additional claims about motives or future trading behavior are made beyond what is recorded in the company disclosures and analyst notes.